Filing Details

Accession Number:
0001209191-21-002246
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-06 17:26:26
Reporting Period:
2021-01-04
Accepted Time:
2021-01-06 17:26:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1623526 Stoke Therapeutics Inc. STOK Pharmaceutical Preparations (2834) 471144582
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1780085 M. Huw Nash C/O Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford MA 01730
Coo & Cbo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-04 5,700 $2.19 5,732 No 4 M Direct
Common Stock Disposition 2021-01-04 1,500 $57.66 4,232 No 4 S Direct
Common Stock Disposition 2021-01-04 2,200 $59.02 2,032 No 4 S Direct
Common Stock Disposition 2021-01-04 1,800 $59.85 232 No 4 S Direct
Common Stock Disposition 2021-01-04 200 $60.51 32 No 4 S Direct
Common Stock Disposition 2021-01-06 32 $57.14 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-01-04 5,700 $0.00 5,700 $2.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
125,397 2018-12-12 No 4 M Direct
Footnotes
  1. Includes 32 shares of Common Stock acquired under the issuer's employee stock purchase plan on December 31, 2020.
  2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.33 to $58.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.395 to $59.355 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.395 to $60.33 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.50 to $60.515 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.